ACERUS PHARMACEUTICALS CORPORATION TORONTO, ONTARIO--(Marketwired - Jun 12, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the voting results from its annual general and special meeting held on June 12, 2014. The total number of shares represented in person or by proxy at the meeting was 121,019,361, representing 74.19% of Trimel's total issued and outstanding shares.
Shareholders voted in favour of the reappointment of the auditors of the company, in favour of ratifying the amended and restated by-laws of the company and voted as follows in connection with the election of the directors of the company:
| Name | Votes For (%) | Votes Withheld (%) | ||
| Ian Ihnatowycz | 83,341,992 (69.43%) | 36,695,676 (30.57%) | ||
| John Friedrichsen | 120,019,043 (99.99%) | 18,625 (0.01%) | ||
| Stephen Gregory | 119,926,872 (99.91%) | 110,796 (0.09%) | ||
| Matthew Pfeffer | 83,323,600 (69.41%) | 36,714,068 (30.59%) | ||
| Rolf Reininghaus | 119,358,688 (99.43%) | 678,980 (0.57%) | ||
| Tom Rossi | 79,224,277 (66.00%) | 40,813,391 (34.00%) | ||
| Jeffrey Sherman | 78,541,818 (67.69%) | 37,495,850 (32.31%) | ||
| Dr. D. Lorne Tyrrell | 120,006,599 (99.98%) | 31,069 (0.02%) |
For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at ir@trimelpharmaceuticals.com.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.
